Skip to main content

Table 1 Baseline Demographics and Disease Characteristics

From: Plasma-based longitudinal mutation monitoring as a potential predictor of disease progression in subjects with adenocarcinoma in advanced non-small cell lung cancer

  Total Study Cohort(n = 71) Subset of Subjects with Pretreatment Tissue Biopsies(n = 47) Remaining Subjects(n = 24) P-value
Age (years)     0.9466
 Mean (SD) 62.54 (10.0) 62.43 (9.2) 62.75 (11.6)  
 Median 62 62 61.5  
Age, n(%)     0.8108
  < 70 52 (73) 34 (72) 18 (75)  
  > = 70 19 (27) 13 (28) 6 (25)  
Sex, n(%)     0.5282
 Female 26 (37) 16 (34) 10 (42)  
 Male 45 (63) 31 (66) 14 (58)  
ECOG Status, n(%)     0.1672
 0 22 (31) 17 (36) 5 (21)  
 1 44 (62) 28 (60) 16 (67)  
 2 3 (4) 2 (4) 1 (4)  
 3 2 (3) 2 (8)  
Stage, n(%)     0.3136
 IIIA 4 (6) 2 (4) 2 (8)  
 IIIB 8 (11) 7 (15) 1 (4)  
 IV 59 (83) 38 (81) 21 (88)  
Histology, n(%)     0.4137
 Adenocarcinoma 68 (96) 45 (96) 23 (96)  
 Adenocarcinoma|Large cell carcinomaa 1 (1) 1 (4)  
 Adenocarcinoma|Squamous cell carcinomaa 2 (3) 2 (4)  
1 L Therapy Received, n(%)     0.8582
 Chemotherapy Onlyb 31 (44) 21 (45) 10 (42)  
 Chemo+Radiationc 25 (35) 17 (36) 8 (33)  
 Chemo+Targetedd 9 (13) 6 (13) 3 (13)  
 Chemo+Radiation+Targetedd 6 (8) 3 (6) 3 (13)  
Smoking Status, n(%)     0.8495
 Never Smoker 11 (15) 6 (13) 5 (21)  
 Quit more than 5 years ago 9 (13) 6 (13) 3 (13)  
 Quit less than 5 years ago 9 (13) 6 (13) 3 (13)  
 Current Smoker 42 (59) 29 (62) 13 (54)  
  1. ECOG, Eastern Cooperative Oncology Group; SD, standard deviation. aAll subjects received an initial diagnosis of adenocarcinoma; however, additional histology was reported after re-biopsy; bCisplatin/carboplatin plus pemetrexed; cRadiation included for brain or bone metastatic sites; dTargeted therapy was bevacizumab in 13 subjects, erlotinib plus chemotherapy and radiation in 1 subject, and 1 subject received Nivolumab after chemotherapy and bevacizumab